首页> 外文期刊>The Journal of Nuclear Medicine >Targeting tumor angiogenesis: comparison of Peptide and polymer-Peptide conjugates.
【24h】

Targeting tumor angiogenesis: comparison of Peptide and polymer-Peptide conjugates.

机译:靶向肿瘤血管生成:肽和聚合物-肽缀合物的比较。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Endothelial cells in tumor angiogenesis are highly accessible, genetically stable and present unique molecular markers for targeted therapy. Neoplasia is also characterized by enhanced vascular permeability and disordered lymphatics so that both active and passive targeting strategies may play a role in localizing angiogenesis-targeted agents. To investigate the relative importance of these targeting strategies, the tissue biodistribution of both endothelial-specific and nonspecific peptides and their macromolecular peptide-copolymer conjugates were studied in 2 xenograft models of prostate cancer. Tumor-to-normal tissue background ratios (T/B) of these constructs were compared to evaluate the effect of molecular size on blood clearance and nonspecific vascular permeability. METHODS: Water-soluble N-(2-hydroxypropyl)methacrylamide (HPMA) copolymers were synthesized with side chains terminated in a doubly cyclized Arg-Gly-Asp motif KACDCRGDCFCG (RGD4C: active peptide targeting the alpha(V)beta(3) integrin) and KACDCRGECFCG (RGE4C: nonactive peptide). The bioactivity of the polymer conjugates and free peptides was characterized in vitro by endothelial cell adhesion assay. The (99m)Tc(CO)(3)-labeled compounds were injected into SCID mice bearing DU145 or PC-3 prostate tumor xenografts for scintigraphic imaging and necropsy organ counting. RESULTS: HPMA copolymer-RGD4C conjugates showed similar inhibition of cell adhesion as free RGD4C attached to (99m)Tc(CO)(3) chelator N-omega-bis(2-pyridylmethyl)-l-lysine (RGD4C-DPK) and were significantly higher (P < 0.05) than RGE4C, HPMA copolymer-RGE4C, and a hydrolyzed HPMA copolymer precursor. Scintigraphic images obtained at 24 h showed specific tumor localization of HPMA copolymer-RGD4C and RGD4C compared with RGE4C conjugates in both prostate tumor models. Twenty-four-hour necropsy data in the DU145 model showed significantly higher (P < 0.001) tumor localization for HPMA copolymer-RGD4C (4.60 +/- 1.80 %ID/g [percentage injected dose per gram tissue]) and RGD4C-DPK (3.37 +/- 0.32 %ID/g) compared with HPMA copolymer-RGE4C (1.24 +/- 0.15 %ID/g) and RGE4C-DPK (0.32 +/- 0.04 %ID/g). Similar results were observed in the PC-3 model. Moreover, higher T/B for the polymer conjugates indicated reduced extravasation of the targeted polymeric conjugates in normal tissues. CONCLUSION: Specific molecular targeting of the alpha(v)beta(3) integrin and nonspecific vascular permeability are both significant in the relative tumor localization of polymeric conjugates of RGD4C. Extravascular leak in nonspecific organs appears to be a major factor in reducing the T/B for the peptide molecules.
机译:肿瘤血管生成中的内皮细胞是高度可访问的,遗传稳定的,并提供了用于靶向治疗的独特分子标记。瘤形成的特征还在于增强的血管通透性和淋巴管紊乱,因此主动和被动靶向策略均可在定位靶向血管生成的药物中发挥作用。为了研究这些靶向策略的相对重要性,在2种前列腺癌异种移植模型中研究了内皮特异性和非特异性肽及其大分子肽-共聚物共轭物的组织生物分布。比较了这些构建体的肿瘤与正常组织的背景比(T / B),以评估分子大小对血液清除率和非特异性血管通透性的影响。方法:合成水溶性N-(2-羟丙基)甲基丙烯酰胺(HPMA)共聚物,侧链终止于双环化的Arg-Gly-Asp基序KACDCRGDCFCG(RGD4C:靶向α(V)beta(3)整联蛋白的活性肽)和KACDCRGECFCG(RGE4C:非活性肽)。通过内皮细胞粘附测定体外表征了聚合物缀合物和游离肽的生物活性。将(99m)Tc(CO)(3)标记的化合物注射到带有DU145或PC-3前列腺肿瘤异种移植物的SCID小鼠中,以进行闪烁显像和尸检器官计数。结果:HPMA共聚物-RGD4C共轭物显示出对细胞粘附的抑制作用,与​​附着在(99m)Tc(CO)(3)螯合剂N-ω-双(2-吡啶基甲基)-1-赖氨酸(RGD4C-DPK)上的游离RGD4C类似。显着高于(P <0.05)RGE4C,HPMA共聚物-RGE4C和水解的HPMA共聚物前体。在两个前列腺肿瘤模型中,与RGE4C共轭物相比,在24小时获得的闪烁图像显示HPMA共聚物-RGD4C和RGD4C的特异性肿瘤定位。 DU145模型中的24小时尸检数据显示HPMA共聚物-RGD4C(4.60 +/- 1.80%ID / g [每克组织注射剂量的百分比])和RGD4C-DPK的肿瘤定位显着更高(P <0.001) 3.37 +/- 0.32%ID / g),而HPMA共聚物-RGE4C(1.24 +/- 0.15%ID / g)和RGE4C-DPK(0.32 +/- 0.04%ID / g)。在PC-3模型中观察到了相似的结果。此外,聚合物缀合物的更高的T / B表明在正常组织中靶向聚合物缀合物的外渗减少。结论:α(v)beta(3)整联蛋白的特定分子靶向和非特异性血管通透性在RGD4C聚合共轭物的相对肿瘤定位中均很重要。非特异性器官中的血管外渗漏似乎是降低肽分子T / B的主要因素。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号